Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Apr 15.

Published in final edited form as: Ann Rheum Dis. 2021 Mar 19;80(8):1100–1101. doi: 10.1136/annrheumdis-2021-220231

Local site and systemic adverse reactions in patients with rheumatic and musculoskeletal diseases within the first week following the first dose of the SARS-CoV-2 vaccination. Mild: does not interfere with activity, moderate: some interference with activity, severe: prevents daily activity. Severe, Moderate, Mild, BNT162b2, mRNA-1273.

Inline graphic — Local site and systemic adverse reactions in patients with rheumatic and musculoskeletal diseases within the first week following the first dose of the SARS-CoV-2 vaccination. Mild: does not interfere with activity, moderate: some interference with activity, severe: prevents daily activity. Severe, Moderate, Mild, BNT162b2, mRNA-1273.